A novel cobiotic-based preventive approach against high-fat diet-induced adiposity, nonalcoholic fatty liver and gut derangement in mice

International Journal of Obesity

Volumn 40, Issue 3, 2016, Pages 487-496

  Singh, D P ^a,b   Khare, P ^a,b   Zhu, J ^c   Kondepudi, K K ^a   Singh, J ^a   Baboota, R K ^a   Boparai, R K ^d   Khardori, R ^e   Chopra, K ^b   Bishnoi, M ^a  

^a NATIONAL AGRI FOOD BIOTECHNOLOGY INSTITUTE   (India)

^b PANJAB UNIVERSITY   (India)

^c BioNeutra North America Incorporation   (Canada)

^d Government College for Girls   (India)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CECAL SHORT CHAIN FATTY ACID; CYTOKINE; GLUCAGON; GLUCOKINASE; GLUCOSE; GLUCOSE TRANSPORTER 4; GLUTATHIONE; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE TYPE 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOMALTOOLIGOSACCHARIDE; LIPOPOLYSACCHARIDE; LYCOPENE; MALONALDEHYDE; NITRITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PREBIOTIC AGENT; RESISTIN; SHORT CHAIN FATTY ACID; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CAROTENOID; GLUCAN; ISOMALTOHEPTAOSE;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY MASS; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; ENDOTOXEMIA; ENTEROPATHY; FATTY ACID SYNTHESIS; FEEDING BEHAVIOR; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GONADAL FAT; GUT DERANGEMENT; HYPERLEPTINEMIA; HYPOTHALAMUS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIVER; LOCOMOTION; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPLEMENTATION; TREATMENT DURATION; UPREGULATION; WEIGHT GAIN; WEIGHT REDUCTION; ADIPOSE TISSUE; ANIMAL; DIETARY SUPPLEMENT; DISEASE MODEL; INFLAMMATION; PATHOLOGY; RANDOMIZATION;

ADIPOSE TISSUE; ADIPOSITY; ANIMALS; CAROTENOIDS; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; GLUCANS; INFLAMMATION; INSULIN RESISTANCE; MALE; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RANDOM ALLOCATION; WEIGHT GAIN;

EID: 84960802788     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2015.197     Document Type: Article

References (53)

1. Frohnert BI, Jacobs Jr. DR, Steinberger J, Moran A, Steffen LM, Sinaiko AR. Relation between serum free fatty acids and adiposity, insulin resistance, and cardiovascular risk factors from adolescence to adulthood. Diabetes 2013; 62: 3163-3169.
2. Imamura F, Mukamal KJ, Meigs JB, Luchsinger JA, Ix JH, Siscovick DS, et al. Risk factors for type 2 diabetes mellitus preceded by beta-cell dysfunction, insulin resistance, or both in older adults: the Cardiovascular Health Study. Am J Epidemiol 2013; 177: 1418-1429.
3. Gilbert CA, Slingerland JM. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu Rev Med 2013; 64: 45-57.
4. Louie SM, Roberts LS, Nomura DK. Mechanisms linking obesity and cancer. Biochim Biophys Acta 2013; 1831: 1499-1508.
5. Baboota RK, Bishnoi M, Ambalam P, Kondepudi KK, Sarma SM, Boparai RK, et al. Functional food ingredients for the management of obesity and associated co-morbidities - a review. J Funct Foods 2013; 5: 997-1012.
6. Bakker GC, van Erk MJ, Pellis L, Wopereis S, Rubingh CM, Cnubben NH, et al. An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: a nutrigenomics approach. Am J Clin Nutr 2010; 91: 1044-1059.
7. Frost G, Sleeth ML, Sahuri-Arisoylu M, Lizarbe B, Cerdan S, Brody L, et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun 2014; 5: 3611.
8. Arora V, Sachdeva AK, Singh P, Baveja A, Chopra K, Kuhad A. Resveratrol and lycopene in the diet and cancer prevention. In: Preedy V (ed). Cancer. Academic Press: San Diego, 2014; pp 127-138.
9. Ferreira AL, Correa CR. Lycopene bioavailability and its effects on health. In: Lima GPP, Vianello F (eds). Food Quality, Safety and Technology. Springer-Verlag: Wien, 2013; pp 63-76.
10. Goffin D, Delzenne N, Blecker C, Hanon E, Deroanne C, Paquot M. Will isomaltooligosaccharides, a well-Established functional food in Asia, break through the European and American market? The status of knowledge on these prebiotics. Crit Rev Food Sci Nutr 2011; 51: 394-409.
11. Kohmoto T, Fukui F, Takaku H, Mitsuoka T. Dose-response test of isomaltooligosaccharides for increasing fecal bifidobacteria. Agric Biol Chem 1991; 55: 2157-2159.
12. Oku T, Nakamura S. Comparison of digestibility and breath hydrogen gas excretion of fructo-oligosaccharide, galactosyl-sucrose, and isomalto-oligosaccharide in healthy human subjects. Eur J Clin Nutr. 2003; 57: 1150-1156.
13. Mizubuchi H, Yajima T, Aoi N, Tomita T, Yoshikai Y. Isomalto-oligosaccharides polarize Th1-like responses in intestinal and systemic immunity in mice. J Nutr 2005; 135: 2857-2861.
14. Delzenne NM, Williams CM. Prebiotics and lipid metabolism. Curr Opin Lipidol 2002; 13: 61-67.
15. Lee, do K, Park SY, Jang S, Baek EH, Kim MJ, Huh SM, et al. The combination of mixed lactic acid bacteria and dietary fiber lowers serum cholesterol levels and fecal harmful enzyme activities in rats. Arch Pharm Res 2011; 34: 23-29.
16. Frece J, Kos B, Svetec IK, Zgaga Z, Beganovic J, Lebos A, et al. Synbiotic effect of Lactobacillus helveticus M92 and prebiotics on the intestinal microflora and immune system of mice. J Dairy Res 2009; 76: 98-104.
17. Greenway F, Wang S, Heiman M. A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report. Benef Microbes 2014; 5: 29-32.
18. Delzenne NM, Neyrinck AM, Backhed F, Cani PD. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 2011; 7: 639-646.
19. Murtaza N, Baboota RK, Jagtap S, Singh DP, Khare P, Sarma SM, et al. Finger millet bran supplementation alleviates obesity-induced oxidative stress, inflammation and gut microbial derangements in high-fat diet-fed mice. Br J Nutr 2014; 112: 1447-1458.
20. Baboota RK, Murtaza N, Jagtap S, Singh DP, Karmase A, Kaur J, et al. Capsaicininduced transcriptional changes in hypothalamus and alterations in gut microbial count in high fat diet fed mice. J Nutr Biochem 2014; 25: 893-902.
21. Anhe FF, Roy D, Pilon G, Dudonne S, Matamoros S, Varin TV, et al. A polyphenolrich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut 2015; 64: 872-883.
22. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-Driven improvement of gut permeability. Gut 2009; 58: 1091-1103.
23. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470-1481.
24. Gummesson A, Carlsson LM, Storlien LH, Backhed F, Lundin P, Lofgren L, et al. Intestinal permeability is associated with visceral adiposity in healthy women. Obesity (Silver Spring) 2011; 19: 2280-2282.
25. Rapin JR, Wiernsperger N. Possible links between intestinal permeablity and food processing: a potential therapeutic niche for glutamine. Clinics 2010; 65: 635-643.
26. Caesar R, Fåk F, Bäckhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. J Intern Med 2010; 268: 320-328.
27. Sahin H, Trautwein C, Wasmuth HE. TLR4 stresses the liver. Gut 2012; 61: 1241-1242.
28. Hu Y, Ketabi A, Buchko A, Gänzle MG. Metabolism of isomalto-oligosaccharides by Lactobacillus reuteri and bifidobacteria. Lett Appl Microbiol 2013; 57: 108-114.
29. Ganzle MG, Follador R. Metabolism of oligosaccharides and starch in lactobacilli: a review. Front Microbiol 2012; 3: 340.
30. Koleva P, Ketabi A, Valcheva R, Gänzle MG, Dieleman LA. Chemically defined diet alters the protective properties of fructo-oligosaccharides and isomaltooligosaccharides in HLA-B27 transgenic rats. PLoS One 2014; 9: e111717.
31. Ghavipour M, Sotoudeh G, Ghorbani M. Tomato juice consumption improves blood antioxidative biomarkers in overweight and obese females. Clin Nutr 2015; 34: 805-809.
32. Luvizotto Rde A, Nascimento AF, Imaizumi E, Pierine DT, Conde SJ, Correa CR, et al. Lycopene supplementation modulates plasma concentrations and epididymal adipose tissue mRNA of leptin, resistin and IL-6 in diet-induced obese rats. Br J Nutr 2013; 110: 1803-1809.
33. Riso P, Pinder A, Santangelo A, Porrini M. Does tomato consumption effectively increase the resistance of lymphocyte DNA to oxidative damage? Am J Clin Nutr 1999; 69: 712-718.
34. Kim AY, Jeong Y-J, Park YB, Lee M-K, Jeon S-M, McGregor RA, et al. Dose dependent effects of lycopene enriched tomato-wine on liver and adipose tissue in high-fat diet fed rats. Food Chem 2012; 130: 42-48.
35. Gouranton E, Thabuis C, Riollet C, Malezet-Desmoulins C, El Yazidi C, Amiot MJ, et al. Lycopene inhibits proinflammatory cytokine and chemokine expression in adipose tissue. J Nutr Biochem 2011; 22: 642-648.
36. Sesso HD, Buring JE, Norkus EP, Gaziano JM. Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in men. Am J Clin Nutr 2005; 81: 990-997.
37. Rissanen TH, Voutilainen S, Nyyssonen K, Lakka TA, Sivenius J, Salonen R, et al. Low serum lycopene concentration is associated with an excess incidence of acute coronary events and stroke: the Kuopio Ischaemic Heart Disease Risk Factor Study. Br J Nutr 2001; 85: 749-754.
38. Ip BC, Liu C, Ausman LM, von Lintig J, Wang XD. Lycopene attenuated hepatic tumorigenesis via differential mechanisms depending on carotenoid cleavage enzyme in mice. Cancer Prev Res (Phila) 2014; 7: 1219-1227.
39. Bernal C, Martin-Pozuelo G, Lozano AB, Sevilla A, Garcia-Alonso J, Canovas M, et al. Lipid biomarkers and metabolic effects of lycopene from tomato juice on liver of rats with induced hepatic steatosis. J Nutr Biochem 2013; 24: 1870-1881.
40. Reid BN, Ables GP, Otlivanchik OA, Schoiswohl G, Zechner R, Blaner WS, et al. Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis. J Biol Chem 2008; 283: 13087-13099.
41. Tsukita S, Yamada T, Uno K, Takahashi K, Kaneko K, Ishigaki Y, et al. Hepatic glucokinase modulates obesity predisposition by regulating BAT thermogenesis via neural signals. Cell Metab 2012; 16: 825-832.
42. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 2014; 371: 2237-2238.
43. Samuel VT, Beddow SA, Iwasaki T, Zhang XM, Chu X, Still CD, et al. Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with type 2 diabetes. Proc Natl Acad Sci USA 2009; 106: 12121-12126.
44. Charbonneau A, Couturier K, Gauthier MS, Lavoie JM. Evidence of hepatic glucagon resistance associated with hepatic steatosis: reversal effect of training. Int J Sports Med 2005; 26: 432-441.
45. Eaton RP, Schade DS. Glucagon resistance as a hormonal basis for endogenous hyperlipemia. Lancet 1973; 301: 973-974.
46. Mighiu PI, Yue JT, Filippi BM, Abraham MA, Chari M, Lam CK, et al. Hypothalamic glucagon signaling inhibits hepatic glucose production. Nat Med 2013; 19: 766-772.
47. Dalamaga M, Chou SH, Shields K, Papageorgiou P, Polyzos SA, Mantzoros CS. Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell Metab 2013; 18: 29-42.
48. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770.
49. Schwartz MW, Woods SC, Porte Jr. D , Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-671.
50. Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-Associated resistance to insulin. Nat Immunol 2014; 15: 423-430.
51. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, et al. Interleukin-6-Deficient mice develop mature-onset obesity. Nat Med 2002; 8: 75-79.
52. Covarrubias AJ, Horng T. IL-6 strikes a balance in metabolic inflammation. Cell Metab 2014; 19: 898-899.
53. Ip BC, Hu KQ, Liu C, Smith DE, Obin MS, Ausman LM, et al. Lycopene metabolite, apo-10'-lycopenoic acid, inhibits diethylnitrosamine-initiated, high fat diet-promoted hepatic inflammation and tumorigenesis in mice. Cancer Prev Res (Phila) 2013; 6: 1304-1316.